Completed PHASE4 INTERVENTIONAL 2-arm NCT02137863

Efficacy of Dexmedetomidine in Preventing Contrast Induced Nephropathy

Phase 4 Study of Dexmedetomidine Effects on Preventing Contrast Induced Nephropathy

Sponsor: TC Erciyes University

Conditions Radiographic Contrast Agent Nephropathy

Interventions 0.9 % NaCl Dexmedetomidine

Updated 5 times since 2017 Last updated: May 13, 2014 Started: Jun 30, 2011 Primary completion: Jun 30, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Radiographic Contrast Agent Nephropathy and is currently completed. TC Erciyes University leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jun 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TC Erciyes University

Data source: TC Erciyes University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.